Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents

Chemical Biology and Drug Design

Volumn 75, Issue 1, 2010, Pages 106-114

  Mazzoni, Orazio ^a   Diurno, Maria V ^a   Di Bosco, Antonio M ^a   Novellino, Ettore ^a   Grieco, Paolo ^a   Esposito, Giovanni ^a   Bertamino, Alessia ^a   Calignano, Antonio ^a   Russo, Roberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aminoalkylindole analogs; Analgesic agents; Cannabimimetic agents; CB1 receptor; SAR study

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 CHLORO 3 (NAPHTHALEN 1 YLIMINO) 1 (2 MORPHOLIN 4 YLETHYL) 1,3 DIHYDROINDOL 2 ONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; FORMALDEHYDE; INDOLE DERIVATIVE; PRAVADOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZINES; BINDING SITES; BRAIN; CANNABINOIDS; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; INDOLES; MORPHOLINES; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1;

EID: 71449123113     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00910.x     Document Type: Article

References (50)

1. Pertwee G.R. (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95 : 165 174.
2. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., Romero J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic placque-associated glia in Alzheimer's disease brains. J Neurosci 23 : 11136 11141.
3. Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B.J. (1997) Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12 : 913 919.
4. Rice A.S. (2001) Cannabinoids and pain. Curr Opin Investig Drugs 2 : 399 414.
5. Di Carlo G., Izzo A.A. (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 12 : 39 49.
6. Porter A.C., Felder C.C. (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90 (1 45 60.
7. Dow R.L., Carpino P.A., Hadcock J.R., Black S.C., Iredale P.A., DaSilva-Jardine P., Shneider S.R., Paight E.S., Griffith D.A., Scott D.O., O'Connor R.E., Nduaka C.I. (2009) Discovery of 2-(2-Chlorophenyl)-3-(4- chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4] oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. J Med Chem 52 : 652 2655.
8. Hurst D., Umejiego U., Lynch D., Seltzman H., Hyatt S., Roche M., McAllister S., Fleischer D., Kapur A., Abood M., Shi S., Jones J., Lewis D., Reggio P. (2006) Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/Lysine3.28(192) Interaction. J Med Chem 49 : 5969 5987.
9. Thornton-Jones Z.D., Vickers S.P., Clifton P.G. (2005) SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 179 : 452 460.
10. Doggrell S.A. (2005) Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Expert Opin Investig Drugs 14 : 339 342.
11. Williamson E.M., Evans F.J. (2000) Cannabinoids in clinical practice. Drugs 60 : 1303 1314.
12. De Vry J., Schreiber R., Eckel G., Jentzsch K.R. (2004) Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 483 : 55 63.
13. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., Betz A.J., Ishiwari K., Makriyannis A., Salamone J.D. (2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14 : 583 588.
14. Gambi F., de Berardis D., Sepede G., Quartesan R., Calcagni E., Salerno R.M., Conti C.M.V., Ferro F.M. (2005) Cannabinoid receptors and their relationships with neuropsychiatric disorders. Int J Immunopathol Pharmacol 18 : 15 19.
15. Zavitsanou K., Garrick T., Huang X.F. (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28 (2 355 360.
16. 2 receptor ligands. Mini Rev Med Chem 5 : 641 649.
17. 1 cannabinoid receptor. J Med Chem 48 : 6386 6392.
18. Willis P.G., Pavlova O.A., Chefer S.I., Vaupel D.B., Mukhin A.G., Horti A.G. (2005) Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem 48 : 5813 5822.
19. Page D., Yang H., Brown W., Walpole C., Fleurent M., Fyfe M., Gaudreault F., St-Onge S. (2007) New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists. Bioorg Med Chem Lett 17 : 6183 6187.
20. Adam J., Cowley P.M., Kiyoi T., Morrison A.J., Mort C.J.W. (2006) Recent progress in cannabinoid research. Prog Med Chem 44 : 207 329.
21. Kai H., Morioka Y., Murashi T., Morita K., Shinonome S., Nakazato H., Kawamoto K. et al. (2007) 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receètor agonists. Part 1: discovery of CB2 receptor selective compounds. Bioorg Med Chem Lett 17 : 4030 4034. (Pubitemid 46920922)
22. 2 receptors: steric and electronic effects of naphtoyl substituent. New highly selective CB2 receptor agonists. Bioorg Med Chem 13 : 89 112.
23. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C., Chippari S.M., Grego J.D., Kullnig R.K., Daley G.T. (1992) Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35 : 124 135.
24. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2); identification of cannabinoid receptor subtype selective agonists. J Pharmacol Exp Ther 278 : 989 999.
25. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdaön R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40 : 471 478.
26. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263 : 1118 1126.
27. Bell M.R., D'Ambra T.E., Kumar V., Eissenstat M.A., Herrmann J.L., Wetzel J.R. Jr., Rosi D. et al. (1991) Antinociceptive (aminoalkyl) indoles. J Med Chem 34 : 1099 1100.
28. Pacheco M., Childers S.R., Arnold R., Casiano F., Ward S.J. (1991) Amminoalkylindoles: action on specific G-protein-linked receptors. J Pharmacol Exp Ther 257 : 170 183.
29. Xie X.Q., Eissenstat M.A., Makriyannis A. (1995) Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci 56 : 1963 1970.
30. Ward S.J., Mastriani D., Casiano F., Arnold R. (1990) Pravadoline: profile in isolated tissue preparations. J Pharmacol Exp Ther 255 : 1230 1239.
31. Devane W.A., Dysarz F.A. III., Johnson M.R., Melvin L.S., Howlett A.C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 : 605 613.
32. Makriyannis A., Rapaka R.S. (1990) The molecular basis of cannabinoid activity. Life Sci 47 : 2173 2184.
33. Xie X., Han X., Chen J., Eissenstat M., Makriyannis A. (1999) High resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype, WJN55212-2. J Med Chem 42 : 4021 4027.
34. Shim J.-Y., Howlett A.C. (2006) WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. J. Chem. Inf. Model. 46 : 1286 1300.
35. Calignano A., La Rana G., Piomelli D. (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419 : 191 198.
36. Kolesnikov Y., Cristea M., Osknam G., Torosjan A., Wilson R. (2004) Evaluation of the tail formalin test in mice as a new model to assess local analgesic effects. Brain Res 1029 : 217 223.
37. Abbot F.V., Franklin K.B., Westbrook R.F. (1995) The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain 60 : 91 102.
38. Dubuisson D., Dennis S.G. (1977) The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. Pain 4 : 161 174.
39. Eissenstat M.A., Bell M.R., D'Ambra T.E., Alexander E.J., Daum S.J., Ackerman J.H., Gruett M.D. et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 38 : 3094.
40. Diaz P., Xu J., Astruc-Diaz F., Pan H.M., Brown D.L., Naguib M. (2008) Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem 51 : 4932 4947.
41. Diaz P., Phatak S.S., Xu J., Astruc-Diaz F., Cavasotto C.N., Naguib M. (2009) 6-methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. J Med Chem 52 : 433 444.
42. Huffman J.W., Padgett L.W. (2005) Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 12 : 1395 1411.
43. Shim J.Y., Collantes E.R., Welsh W.J., Subramaniam B., Howlett A.C., Eissenstat M.A., Ward S.J. (1998) Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. J Med Chem 41 : 4521 4532.
44. Manera C., Tuccinardi T., Martinelli A. (2008) Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem 8 : 370 387.
45. Tarzia G., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Plazzi P.V., Kathuria S., Piomelli D. (2003) Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorg Med Chem 11 : 3965 3973.
46. Brünger A.T., Kuriyan J., Karplus M. (1987) Crystallographic R factor refinement by molecular dynamics. Science 235 : 458 460.
47. Nilges M., Clore G.M., Gronenborn A.M. (1988) Determination of three-dimensional structures of proteins from interproton distance data by dynamical simulated annealing from a random array of atoms. Circumventing problems associated with folding. FEBS Lett 239 : 129 136.
48. Havel T.F. (1991) An evaluation of computational strategies for use in the determination of protein structure from distance constraints obtained by NMR spectroscopy. Prog Biophys Mol Biol 56 : 43 78.
49. Dauber-Osguthorpe P., Roberts V.A., Osguthorpe D.J., Wolff J., Genest M., Hagler A.T. (1988) Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 4 : 31 47.
50. Allinger N.L., Yuh Y.H., Lii J.H. (1989) Molecular mechanics. The MM3 force field for hydrocarbons. 1. J Am Chem Soc 111 : 8551 8566.